---
aliases:
  - Epidermal Growth Factor Receptor
---
EGFR inhibitors are a class of targeted cancer therapies that specifically block the activity of the epidermal growth factor receptor (EGFR), a protein on the surface of cells that, when activated, promotes cell growth and division. Abnormal activation of EGFR is associated with various types of cancers, making it a key target for treatment.

### Key Points About EGFR and EGFR Inhibitors:

1. **Epidermal Growth Factor Receptor (EGFR)**:
   - EGFR is a transmembrane protein with a receptor domain outside the cell and a tyrosine kinase domain inside the cell. It is involved in signaling pathways that regulate cell proliferation, survival, and differentiation.
   - When EGFR binds to its ligands, such as epidermal growth factor (EGF), it undergoes dimerization (pairing with another EGFR molecule), which activates its tyrosine kinase domain. This activation triggers a cascade of downstream signaling pathways, including the MAPK, PI3K/AKT, and JAK/STAT pathways, leading to cell growth and survival.
   - Overexpression or mutations in the EGFR [[gene]] can result in uncontrolled cell division and cancer. This is seen in various cancers, including non-small cell lung cancer ([[non–small-cell lung cancer]]), colorectal cancer, and head and neck cancers.

2. **Types of EGFR Inhibitors**:
   - EGFR inhibitors can be broadly classified into two main categories: **tyrosine [[Kinase Inhibitors]] ([[Tyrosine Kinase-EGFR Inhibitors]])** and **[[Monoclonal antibodies]]**.

   - **Tyrosine [[Kinase Inhibitors]] ([[Tyrosine Kinase-EGFR Inhibitors]])**:
     - [[Tyrosine Kinase-EGFR Inhibitors]] are small molecules that inhibit the tyrosine kinase domain of EGFR, blocking its ability to activate downstream signaling pathways.
     - **Examples**:
       - **[[erlotinib]] (Tarceva)**: Used primarily for the treatment of EGFR-mutant [[non–small-cell lung cancer]].
       - **[[gefitinib]] (Iressa)**: Also used for EGFR-mutant [[non–small-cell lung cancer]].
       - **[[afatinib]] (Gilotrif)**: An irreversible TKI used for [[non–small-cell lung cancer]] with specific EGFR mutations.
       - **[[osimertinib]] (Tagrisso)**: A third-generation TKI that targets both EGFR mutations and T790M resistance mutations in [[non–small-cell lung cancer]].
     - These [[Boxes/Temple College Nursing Program/LVN Program/Fall 24/Pharmacology/Drugs/Drugs|Drugs]] are typically taken orally and are effective in cancers that harbor specific activating mutations in the EGFR [[gene]].

   - **[[Monoclonal antibodies]]**:
     - These are large molecules that target the extracellular domain of EGFR, preventing it from binding to its ligands and thus blocking receptor activation.
     - **Examples**:
       - **[[cetuximab]] (Erbitux)**: Used to treat metastatic colorectal cancer and head and neck cancer.
       - **[[panitumumab]] (Vectibix)**: Another monoclonal antibody used for metastatic colorectal cancer.
     - These [[Boxes/Temple College Nursing Program/LVN Program/Fall 24/Pharmacology/Drugs/Drugs|Drugs]] are administered intravenously.

3. **Clinical Uses**:
   - **Non-Small Cell Lung Cancer ([[non–small-cell lung cancer]])**: EGFR [[Tyrosine Kinase-EGFR Inhibitors]] are commonly used as first-line therapy for patients with [[non–small-cell lung cancer]] who have specific EGFR mutations, such as exon 19 deletions or exon 21 L858R mutations.
   - **Colorectal Cancer**: [[cetuximab]] and [[panitumumab]] are used in the treatment of metastatic colorectal cancer, particularly in patients with wild-type (non-mutated) KRAS and NRAS genes.
   - **Head and Neck Cancers**: [[cetuximab]] is used in combination with radiation therapy or chemotherapy for the treatment of squamous cell [[Carcinoma]] of the head and neck.

4. **Side Effects**:
   - Common side effects of EGFR inhibitors include skin rash, diarrhea, [[Stomatitis]] (inflammation of the [[Mouth]]), and fatigue. The skin rash is often acne-like and can be an indicator of drug efficacy.
   - More serious but less common side effects include interstitial lung disease (ILD), [[Liver]] toxicity, and severe gastrointestinal issues.

5. **Resistance**:
   - Over time, cancers treated with EGFR inhibitors can develop resistance, often through secondary mutations in the EGFR [[gene]], such as the T790M mutation in [[non–small-cell lung cancer]], or through activation of alternative signaling pathways.
   - The development of resistance is a significant challenge, and ongoing research is focused on overcoming this through the development of next-generation inhibitors and combination therapies.

6. **Research and Future Directions**:
   - Research continues to explore the combination of EGFR inhibitors with other therapies, such as immunotherapy and chemotherapy, to improve outcomes.
   - Newer EGFR inhibitors that target resistant mutations or work in a broader range of cancers are in development.

In summary, EGFR inhibitors are a critical component of targeted cancer therapy, particularly in cancers like [[non–small-cell lung cancer]] and colorectal cancer. They offer a more personalized approach to treatment, though challenges such as resistance and side effects remain areas of active research.